Liminatus Pharma, Inc. (LIMN) stock
LIMNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as LIMNW
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 2/30
$2.68−0.13 (-4.63%)
Close on Nov 18, 2026Market cap $179.99MP/E –Yield –
Liminatus Pharma total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Liminatus Pharma's total debt was $1.44M at Jun 30, 2026. For fiscal 2025 it was $1.44M, down 92.8% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.44M | -92.8% |
| FY2024 | Dec 31, 2024 | $19.97M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.44M | 0.0% |
| Q1 FY2026 | Mar 31, 2026 | $1.44M | -92.8% |
| Q4 FY2025 | Dec 31, 2025 | $1.44M | – |
| Q3 FY2025 | Sep 30, 2025 | $1.44M | – |
| Q2 FY2025 | Jun 30, 2025 | $1.44M | – |
| Q4 FY2024 | Dec 31, 2024 | $19.97M | – |
See a number that looks wrong?